Spindiag: Germany-based molecular point-of-care diagnostic platform spun out of research institute Hahn-Schickard

Spindiag, a Germany-based molecular point-of-care diagnostic platform spun out of research institute Hahn-Schickard and also based on work at University of Freiburg, has obtained €4m ($4.7m) in series A funding from elderly care provider WBG Pflegeheime and one unnamed investor. Spindiag has developed a rapid test to diagnose multidrug-resistant infections. The test is aimed at hospitals, with a view of facilitating a triage of patients suffering from a bacterial infection that are resistant to multiple antibiotics. The series A round will support a market entry of the test in Europe next year. Spindiag previously attracted $1.86m in seed funding in 2017 from private investors.

Source: Heles, Thierry; Global University Venturing